An interventional study of Prostate Tractography for Nerve-Sparing in Prostate Cancer, Erectile Dysfunction Following Radical Prostatectomy and Urinary Incontinence Following Surgical Procedure, sponsored by Massimo Valerio. Recruiting at 1 site in Switzerland. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Massimo Valerio · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 136 studies in Prostatic Neoplasms with a site in Switzerland — 40 open to participants now, 58 under way, 20 of them phase 3. Prostatic Neoplasms · Switzerland.
Among the 136 studies in Prostatic Neoplasms with a site in Switzerland, this one is the 94th largest by planned enrollment of the 107 interventional ones that give a count, is one of 13 that started in 2026, is one of 23 with no phase, reaches primary completion later than 25 of the 57 other live ones, and was the 134th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →40 of the 136 studies in Prostatic Neoplasms with a site in Switzerland are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Switzerland
Men only
AstraZeneca · Sites in Switzerland, United States, Austria and 18 more countries
Ages 18+ · Men only
University of Zurich · Sites in Switzerland
Ages 18+ · Men only
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 50+ · Men only · Healthy volunteers
AstraZeneca · Sites in Switzerland, United States, Australia and 21 more countries
Ages 18+ · Men only
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
136 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 31 · Phase 3 43 · Phase 4 3
First in 1992; this study’s year is marked. 13 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 23 is below the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 140 across the 107 interventional studies, 219 across the 28 observational. Of the 71 that completed or were terminated, 16 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 136 have an industry lead sponsor. The 10 most frequent:
Massimo Valerio is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Massimo Valerio has 1 study filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
8 of the studies in Prostatic Neoplasms with a site in Switzerland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT07455097Heinrich-Heine University, DuesseldorfCOMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P) | 2026-12-31 |
| NCT05850182Oncology Institute of Southern SwitzerlandLifestyle Intervention in Patients With Metastatic Prostate Cancer | 2026-12-31 |
| NCT04543799Oncology Institute of Southern SwitzerlandEvaluation of Sleep Quality in Prostate Cancer Patients Undergoing Treatment With Hormonal Therapeutic Approaches and in Patients With Full-resected Early Breast Cancer | 2026-12-31 |
| NCT06776172University Hospital, Basel, SwitzerlandExtended vs. No Pelvic Lymph Node Dissection During Radical Prostatectomy. DISSECTION 2.0. | 2027-02 |
Add all 8 to your calendar (.ics) → With an account.
Among the 136 studies in Prostatic Neoplasms with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Radical prostatectomy (RP) is an effective treatment leading to a high rate of oncological control. However, despite advances in robot-assisted RP, the genito-urinary function, especially erectile function and urinary continence, may be significantly impaired after surgery.
Our study aims to characterize and map the nerve fibers surrounding the prostate before and after surgery using diffusion tensor magnetic resonance imaging (DTI), a non-invasive magnetic resonance imaging (MRI) technique. This relatively new technology, combined with the 3D tractography software, will allow us to create a personalized 3D model of the periprostatic nerves. This virtual model will help us to assess the nerve bundles and how the surgery impacts their integrity. DTI and 3D reconstruction will be performed before and 6 months after surgery.
The pre-surgery 3D virtual model will be overlaid and mapped onto the intraoperative surgical view, providing the surgeon with a visual guide of the nerve fiber organization. At the post-surgery level, the 3D virtual model of the nerve bundles will be compared to the pre-surgery model. Post-treatment changes at 6 months may help assess nerve preservation and their relationship with erectile (dys)function.
The main questions the clinical study aims to answer are:
In Switzerland and Western countries, prostate cancer (PCa) is the most frequently diagnosed solid cancer in men and represents the second leading cause of cancer-related deaths. Similarly, in Geneva, between 1995 and 2021, PCa has been the most common cancer with 8,373 new cases reported.
For patients with prolonged life expectancy harboring high-risk and intermediate-risk disease, radical prostatectomy (RP) is one of the gold standard treatments. While RP is a safe and effective surgical procedure leading to a high rate of cancer control, the genito-urinary function can be severely impaired after surgery since the prostate is closely surrounded by neurovascular fibers that are critical for urinary continence and erectile function. In 1982, Walsh developed the nerve-sparing (NS) procedure to preserve the neurovascular bundles (NVBs) . Nevertheless, accurately identifying the NVBs still remains a challenge nowadays. Despite the advancements made in the area of precision surgery with the advent of 3D robotic-assisted RP (RARP) as well as preoperative planning (particularly with Multiparametric magnetic resonance imaging (mpMRI) providing information about tumor localization and extracapsular extension), erectile dysfunction (ED) is currently the most common post-operative sequela occurring in up to 74.7% of patients. One of the key reasons is linked to the fact that the NVBs are not clearly visible during surgery and are in contact with the prostatic capsule.
Novel intraoperative imaging modalities have emerged to solve this unmet clinical need. First, it has been suggested that assistance can be provided by intraoperative transrectal ultrasound (TRUS) eventually combined with a robotic manipulator. TRUS can identify key anatomical landmarks. However, it is rarely used due to the poor spatial resolution. Second, electrical nerve stimulation offers fast functional feedback for nerve mapping. Although this solution is deliverable, its inconsistent clinical response reduces its efficacy and usefulness. Third, fluorescent imaging allows for a real-time assessment, but its clinical use is limited due to, among others,the toxicity of dyes.
Tractography, mainly used in brain surgery, is an advanced non-invasive imaging technique relying on diffusion tensor imaging (DTI) and algorithms to reconstruct three-dimensional nerve fiber pathways by analyzing directional movement of water molecules in tissues The accuracy of DTI Tractography heavily relies on sophisticated protocols and highly developed technical parameters, which also includes the post-processing aspects. For instance, the number of gradient diffusion directions, b-values affecting the signal-to-noise ratio (SNR) and tract fiber length play a key role, as studied in Nordbrøden's thesis focusing on providing an optimized protocol for periprostatic fiber nerve tracking. Due to inherent complexity, despite being a promising tool, application of tractography for NVB mapping preoperatively has not been well studied yet. To improve functional outcomes, surgeons should be able to rely on a patient-tailored anatomical map to provide personalized nerve-sparing surgery.
Moreover, three-dimensional virtual model (3DVM), reconstructed from classical preoperative MRI done during the diagnostic pathway, are gaining popularity in RARP. Various formats are described; for instance, Virtual Reality (VR) uses a fullly digital immersive environment, whereas Augmented Reality (AR) overlays the 3D model onto the intraoperative view. However, integration of such a tool into clinical practice faces many challenges at each step of the procedure. First, when generating the model, suboptimal image quality and the difficult segmentation task needed for surface rendering (SR) could generate anatomical inaccuracy. Secondly, in AR, the 3DVM needs to be registered to the patient's anatomy (landmarks) using manual or semi-automatic techniques, with fully-automatic registration being the subject of ongoing research . Nonetheless, Schiavina et al (2021) using a manual registration accurately managed a real-time identification of the index lesion with the downside of having a dedicated 3DVM manipulator changing the NS plan in 38.5%.
In this context, given the absence of histopathological validation possible for Tractography, the rationale of this pilot study is to leverage the benefits of DTI imaging for nerve identification and to translate them directly during the surgery.
The trial relies on two distinct parts.
As this pilot study relies mostly on DTI MRI, a non-invasive modality that does not use a contrast agent, and excludes fluorescent dye administration or electrical stimulation, participant burden is limited to the need for this acquisition. As to the first part, according to the Ordinance on Human Research with the Exception of Clinical Trials dated 20 September 2013 and entered into force on 1st January 2014, and particularly Article 7, MRI scans without a contrast medium is associated with minimal risks and burdens and hence falls into the scope of Category A. As to the second part, the AR guidance is purely a non-invasive software-based overlay of MRI data onto the surgeon's view where no additional biological material collection is needed. There will be no new incisions or instruments beyond standard procedure (same surgical steps, trocar placement, dissection planes, etc.). Therefore, this second part is also associated to minimal risks and burdens and falls as well into the scope of Category A.
To address all these challenges, our institution is particularly adequate for many reasons. First, RARP is a procedure performed at an expert-level according to the European Cancer Center Certification Program. Second, prior to each surgery, the case is discussed in a multi-disciplinary setting with proofreading of the MRI by an expert uro-radiologist, Dr. Thomas De Perrot (according to European Society of Urogenital Radiology (ESUR) and EAU Section of Urologic Imaging (ESUI); more than 1000 interpreted MRI). The NS approach can therefore be safely chosen prior to surgery based on radiologic-clinical parameters. Pr. Felix Kurz is a renowned specialist in peripheral nerve imaging while Pr. Michele Diana is a pioneer in AR surgery and multi-level imaging surgical guidance . In addition, the Diagnostic Department, together with the CIBM Center for Biomedical Imaging, received the state-of-the-art MAGNETOM Cima.X (Siemens Healthineers AG, Erlangen, Germany) in June 2025. This advanced 3.0-T MRI system offers the highest magnetic gradients available in routine clinical imaging-reaching up to 200 mT/m. These exceptional gradients are specifically engineered for high-performance diffusion MRI measurements, reducing acquisition times and improving image quality through higher signal-to-noise ratio. In addition to all of the above, the HUG surgical department has performed Robotic AR surgery since 2011.
Regarding the "sex and gender" dimensions, the study concerns patients with PCa.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3 visits are related to the research protocol 1. Informed consent (Day - 30) 2. Preoperative MRI (DTI acquisition) and preoperative PROMs (day -14) 3. Postoperative MRI (DTI acquisition) and postoperative PROMs (day +180) The tractography will be performed according to established best practices. Robot-assisted PR (Day 0) is performed according to standard practice and is not part of the research-specific procedure.
Procedure: Prostate Tractography for Nerve-Sparing
Tractography will be performed according to established best practices. To create the 3DVM, a high-performance workstation equipped with a high-end GPU will be used. ROI placement for nerve tractography and segmentation tasks will be performed semi-automatically using a previously trained nnU-Net pipeline. All inference will be strictly performed locally on this dedicated machine resulting in 4 segment masks (Prostate, Urethra, Index Lesion, Seminal Vesicles) that will be manually reviewed and corrected. The subsequent reconstructed Tractography bundles will be added to create the 3DTVM. The 3DTV model will be overlaid and mapped onto the intraoperative surgical view, providing the surgeon with a visual guide of the nerve fiber organizations (mean surgery time, surgeon feedback etc will be evaluated.)
Evaluation of erectile function at 6-month.
Imaging versus Patient-Reported Outcome Measure (PROM).
Time frame: From surgery (day 0) and at the 6-month follow-up (day 180).
1. Evaluation of urinary function at 6 month follow-up.
Imaging versus Urinary Function Patient-Reported Outcome Measure (PROM).
Time frame: From surgery (day 0) and at the 6-month follow-up (day 180).
Assessment of the feasibility of augmented reality using tractography-based 3D model.
To document the feasibility of augmented reality using a tractography model (operative time).
Time frame: At surgery (day 0)
3. Concordance of pre- and postoperative Diffusion Tensor Imaging.
Evolution of nerve integrity after surgery
Time frame: At the end of the 6-month follow-up (day 180)
Plan to share: No — Exploratory study with a small number of participants
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Dec 2027, 15 months after the start.
Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 15 months is below that.
Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massimo Valerio